Address And Details
Guggenheim Investments, P.O. Box 758567 , Topeka, KS 66675 | |
---|---|
Fund Manager | Michael P. Byrum |
Manager Tenure | 16 Years 11 Months |
Strategy And Objective
The Biotechnology Fund (the Fund) seeks to provide capital appreciation by investing in companies that are involved in the biotechnology industry,including companies involved in research and development, genetic or other biological engineering, and in the design, manufacture, or sale of related biotechnology products or services (Biotechnology Companies). Under normal circumstances, the Fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. The Advisor employs a proprietary quantitative and qualitative methodology to identify Biotechnology Companies in which to invest. The methodology utilizes screens based on price, liquidity, and tradability. Stocks are weighted using a proprietary modified capitalization weighting methodology. The portfolio may be further adjusted to comply with regulatory investment limitations or as determined appropriate by the Advisor.
Equity Sector Breakdown
Health | 66.12% | |
Services | 14.84% | |
Technology | 4.25% | |
NonDurables | 2.63% | |
IndustrialCyclical | 0.88% | |
ConsumerDurables | n/a | |
Energy | n/a | |
Finance | n/a | |
RetailTrade | n/a | |
Utilities | n/a |
Asset Allocation
Asset Type | % Of Allocation | |
---|---|---|
Stocks | 99.31% | |
ForeignStocks | 2.19% | |
Cash | 0.00% | |
Bonds | 0.00% | |
Preferred | 0.00% | |
Convertible | 0.00% | |
Other | 0.00% | |
ForeignBonds | 0.00% | |
ForeignHedged | 0.00% |
Total Net Assets | 17.25 M |
---|
Risk Measures
Criteria | 3 Years | 5 Years | 10 Years |
---|---|---|---|
Alpha | -5.97 | -5.92 | -1.10 |
Beta | 0.82 | 0.92 | 1.05 |
R Squared | 0.50 | 0.51 | 0.40 |
Std Deviation | 21.72 | 21.38 | 22.69 |
Sharpe Ratio | 0.25 | 0.29 | n/a |
Purchase Information
as of 5:38 PM ET 05/19/2022Minimum Initial | $2500 |
---|---|
Minimum Additional | $0 |
Minimum Initial IRA | $1000 |
Performance
Timeframe | Average Annual Current Performance Monthly As Of 04/30/2022 | Average Annual Current Performance Quarterly As Of 03/31/2022 | Avg Annual Current Performance Monthly As Of 04/30/2022 | Avg Annual Current Performance Quarterly As Of 03/31/2022 |
---|---|---|---|---|
1 Year |
|
|
-19.76% | -7.04% |
3 Year |
|
|
+3.82% | +5.47% |
10 Year |
|
|
+11.27% | +12.58% |
Life Of Fund |
|
|
+10.40% | +11.11% |
Top 10 Holdings
Symbol | Company Name | % Of Assets |
---|---|---|
ABBV | ABBVIE INC | 6.95% |
AMGN | AMGEN INC | 4.91% |
MRNA | MODERNA INC | 4.26% |
GILD | GILEAD SCIENCES INC | 4.22% |
REGN | REGENERON PHARMACEUTICALS | 3.66% |
CASH | TOTAL*MONEY MARKET | 3.49% |
VRTX | VERTEX PHARMACEUTICALS INC | 3.36% |
ILMN | ILLUMINA INC | 3.33% |
CTVA | CORTEVA INC | 2.63% |
BGEN | BIOGEN INC | 2.61% |